Format

Send to

Choose Destination
Br J Haematol. 2010 May;149(3):410-3. doi: 10.1111/j.1365-2141.2010.08132.x. Epub 2010 Mar 10.

Asparaginase-related venous thrombosis in UKALL 2003- re-exposure to asparaginase is feasible and safe.

Author information

1
Department of Haematology, Children's Hospital, The John Radcliffe, Oxford, UK. amrana.qureshi@orh.nhs.uk

Abstract

We report the incidence and outcome of venous thrombosis (VT) in the UK acute lymphoblastic leukaemia (ALL) 2003 trial. VT occurred in 59/1824 (3.2%) patients recruited over 5 years with 90% occurring during a period of Asparagine depletion. Pegylated Escherichia Coli Asparaginase (Peg-ASP) 1000 units/m(2) was used throughout. Thirty-four children received further Peg-ASP, most with concurrent heparin prophylaxis. There were no episodes of bleeding or recurrent thrombosis. Optimal Asparagine depletion is central to success of modern regimes for treatment of ALL. This report confirms a significant risk of thrombosis with such therapy, but demonstrates that re-exposure to Asparaginase is feasible and safe.

[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center